Clinical studyTwelve-month Results of the EverFlex Stent in the Superficial Femoral Artery
Section snippets
Materials and Methods
From June 2008 to January 2010, 53 patients with de novo, restenotic, or reoccluded SFA lesions were treated with the Protégé EverFlex stent (ev3) at our interventional unit. This dedicated, self-expanding stent is premounted on a 6-F, 0.035-inch, over-the-wire delivery system. For clinical use, the stent is available in various lengths, starting from 60 to 200 mm, and in two diameters of 6 and 7 mm. In all patients with PAD who were recruited for therapeutic angiography, the clinical symptoms
Results
Of the 53 patients included in this retrospective study, a follow-up examination was performed in 46. Among the remaining seven patients, five had died and two had moved to another location. One target lesion was treated in each of 50 patients, and three patients underwent treatment of two contiguous target lesions in the same SFA. Table 1 shows the demographic data and the risk factors of the treated patients.
The mean lesion length was 9.4 cm ± 5.3 (Fig 1). Of 56 lesions, 26 (46%) involved
Discussion
For the treatment of complex SFA lesions associated with extensive occlusive disease, the indications for endovascular interventional procedures are growing and the results are promising. Considering the fact that current stent designs are constantly being optimized and that the technical developments of the devices and procedures are immense, some authors support present interventional procedures and strongly recommend extending the spectrum of therapeutic interventional techniques (8, 9, 10,
References (12)
- et al.
Prevalence and clinical impact of stent fractures after femoropopliteal stenting
J Am Coll Cardiol
(2005) - et al.
Changing pattern of surgical revascularization for critical limb ischemia over 12 years: endovascular vs open bypass surgery
J Vasc Surg
(2006) - et al.
Stenting versus above knee polytetrafluoroethylene bypass for TransAtlantic Inter-Society Consensus-II C and D superficial femoral artery disease
J Vasc Surg
(2008) - et al.
Outcomes of endovascular interventions for TASC II B and C femoropopliteal lesions
J Vasc Surg
(2008) - et al.
Efficacious use of nitinol stents in the femoral and popliteal arteries
J Vasc Surg
(2003) - et al.
Endovascular interventions in iliac and infrainguinal occlusive artery disease
J Intervent Cardiol
(2004)
Cited by (11)
IN.PACT™ Admiral™ drug-coated balloon: Durable, consistent and safe treatment for femoropopliteal peripheral artery disease
2017, Advanced Drug Delivery ReviewsResults of primary stent therapy for femoropopliteal peripheral arterial disease at 7 years
2016, Journal of Vascular SurgeryCitation Excerpt :Similarly, miscellaneous studies revealed satisfying midterm and long-term outcomes of nitinol stent implantation, whereas the reported PPR at 5 years varies between 41% and 79.5%.4,9,10 In contrast to the findings of Diehl et al,11 the lesion length did not affect stent performance. Notably, the decline of PPR was not continuous, and a significant loss of patency was observed during the first 12 months and between 36 and 48 months after the procedure.
SUPERA interwoven nitinol stent outcomes in above-knee intErventions (SAKE) study
2014, Journal of Vascular and Interventional RadiologyDirect stent puncture technique for intraluminal stent recanalization in the superficial femoral and popliteal arteries in-stent occlusion: Outcomes from a prospective clinical analysis of diabetics with critical limb ischemia
2013, Cardiovascular Revascularization MedicineCitation Excerpt :Important advances in technology have led to the development of self-expanding nitinol stents, which have significantly improved intermediate outcomes of superficial femoral artery (SFA) stenting in several prospective clinical trials [5–10]. However, in a long-term follow up [11,12] the most important complication of endovascular stenting is the in-stent occlusion [13–18]. The options to treat in-stent occlusion are endovascular or open surgery intervention.
Ever done or moving on?
2012, Journal of Vascular and Interventional RadiologyA review on femoropopliteal arterial deformation during daily lives and nickel-titanium stent properties
2022, Journal of Medical Engineering and Technology
None of the authors have identified a conflict of interest.